216 related articles for article (PubMed ID: 24778153)
1. Somatic mutation as a mechanism of Wnt/β-catenin pathway activation in CLL.
Wang L; Shalek AK; Lawrence M; Ding R; Gaublomme JT; Pochet N; Stojanov P; Sougnez C; Shukla SA; Stevenson KE; Zhang W; Wong J; Sievers QL; MacDonald BT; Vartanov AR; Goldstein NR; Neuberg D; He X; Lander E; Hacohen N; Regev A; Getz G; Brown JR; Park H; Wu CJ
Blood; 2014 Aug; 124(7):1089-98. PubMed ID: 24778153
[TBL] [Abstract][Full Text] [Related]
2. Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/beta-catenin pathway.
Lu D; Liu JX; Endo T; Zhou H; Yao S; Willert K; Schmidt-Wolf IG; Kipps TJ; Carson DA
PLoS One; 2009 Dec; 4(12):e8294. PubMed ID: 20011538
[TBL] [Abstract][Full Text] [Related]
3. Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia.
Khan AS; Hojjat-Farsangi M; Daneshmanesh AH; Hansson L; Kokhaei P; Österborg A; Mellstedt H; Moshfegh A
Tumour Biol; 2016 Sep; 37(9):11947-11957. PubMed ID: 27086035
[TBL] [Abstract][Full Text] [Related]
4. Aberrant splicing of the E-cadherin transcript is a novel mechanism of gene silencing in chronic lymphocytic leukemia cells.
Sharma S; Lichtenstein A
Blood; 2009 Nov; 114(19):4179-85. PubMed ID: 19745069
[TBL] [Abstract][Full Text] [Related]
5. Metadherin contributes to the pathogenesis of chronic lymphocytic leukemia partially through Wnt/β-catenin pathway.
Li PP; Feng LL; Chen N; Ge XL; Lv X; Lu K; Ding M; Yuan D; Wang X
Med Oncol; 2015 Feb; 32(2):479. PubMed ID: 25575438
[TBL] [Abstract][Full Text] [Related]
6. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia.
Lu D; Zhao Y; Tawatao R; Cottam HB; Sen M; Leoni LM; Kipps TJ; Corr M; Carson DA
Proc Natl Acad Sci U S A; 2004 Mar; 101(9):3118-23. PubMed ID: 14973184
[TBL] [Abstract][Full Text] [Related]
7. Old and new news in CLL: "It's the pathway, stupid!".
Egle A
Blood; 2014 Aug; 124(7):989-90. PubMed ID: 25124780
[No Abstract] [Full Text] [Related]
8. Variation in WNT genes expression in different subtypes of chronic lymphocytic leukemia.
Memarian A; Hojjat-Farsangi M; Asgarian-Omran H; Younesi V; Jeddi-Tehrani M; Sharifian RA; Khoshnoodi J; Razavi SM; Rabbani H; Shokri F
Leuk Lymphoma; 2009 Dec; 50(12):2061-70. PubMed ID: 19863181
[TBL] [Abstract][Full Text] [Related]
9. Decreased WNT3 expression in chronic lymphocytic leukaemia is a hallmark of disease progression and identifies patients with worse prognosis in the subgroup with mutated IGHV.
Poppova L; Janovska P; Plevova K; Radova L; Plesingerova H; Borsky M; Kotaskova J; Kantorova B; Hlozkova M; Figulova J; Brychtova Y; Machalova M; Urik M; Doubek M; Kozubik A; Pospisilova S; Pavlova S; Bryja V
Br J Haematol; 2016 Dec; 175(5):851-859. PubMed ID: 27651098
[TBL] [Abstract][Full Text] [Related]
10. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
Wiestner A; Rosenwald A; Barry TS; Wright G; Davis RE; Henrickson SE; Zhao H; Ibbotson RE; Orchard JA; Davis Z; Stetler-Stevenson M; Raffeld M; Arthur DC; Marti GE; Wilson WH; Hamblin TJ; Oscier DG; Staudt LM
Blood; 2003 Jun; 101(12):4944-51. PubMed ID: 12595313
[TBL] [Abstract][Full Text] [Related]
11. Blockage of Wnt/β-Catenin Signaling by Nanoparticles Reduces Survival and Proliferation of CLL Cells In Vitro-Preliminary Study.
Franiak-Pietryga I; Maciejewski H; Ziemba B; Appelhans D; Voit B; Robak T; Jander M; Treliński J; Bryszewska M; Borowiec M
Macromol Biosci; 2017 Nov; 17(11):. PubMed ID: 28762636
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic dysregulation of the Wnt signalling pathway in chronic lymphocytic leukaemia.
Chim CS; Pang R; Liang R
J Clin Pathol; 2008 Nov; 61(11):1214-9. PubMed ID: 18765431
[TBL] [Abstract][Full Text] [Related]
13. LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis.
Gutierrez A; Tschumper RC; Wu X; Shanafelt TD; Eckel-Passow J; Huddleston PM; Slager SL; Kay NE; Jelinek DF
Blood; 2010 Oct; 116(16):2975-83. PubMed ID: 20595513
[TBL] [Abstract][Full Text] [Related]
14. Dysregulation of TNFα-induced necroptotic signaling in chronic lymphocytic leukemia: suppression of CYLD gene by LEF1.
Liu P; Xu B; Shen W; Zhu H; Wu W; Fu Y; Chen H; Dong H; Zhu Y; Miao K; Xu W; Li J
Leukemia; 2012 Jun; 26(6):1293-300. PubMed ID: 22157808
[TBL] [Abstract][Full Text] [Related]
15. Circular RNA circ-CBFB promotes proliferation and inhibits apoptosis in chronic lymphocytic leukemia through regulating miR-607/FZD3/Wnt/β-catenin pathway.
Xia L; Wu L; Bao J; Li Q; Chen X; Xia H; Xia R
Biochem Biophys Res Commun; 2018 Sep; 503(1):385-390. PubMed ID: 29902450
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of Sox7 is associated with aberrant activation of Wnt/b-catenin signaling in endometrial cancer.
Chan DW; Mak CS; Leung TH; Chan KK; Ngan HY
Oncotarget; 2012 Dec; 3(12):1546-56. PubMed ID: 23295859
[TBL] [Abstract][Full Text] [Related]
17. E-cadherin gene re-expression in chronic lymphocytic leukemia cells by HDAC inhibitors.
Jordaan G; Liao W; Sharma S
BMC Cancer; 2013 Feb; 13():88. PubMed ID: 23432814
[TBL] [Abstract][Full Text] [Related]
18. ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress.
Chapman CM; Sun X; Roschewski M; Aue G; Farooqui M; Stennett L; Gibellini F; Arthur D; Pérez-Galán P; Wiestner A
Clin Cancer Res; 2012 Apr; 18(7):1979-91. PubMed ID: 22351695
[TBL] [Abstract][Full Text] [Related]
19. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway.
Flahaut M; Meier R; Coulon A; Nardou KA; Niggli FK; Martinet D; Beckmann JS; Joseph JM; Mühlethaler-Mottet A; Gross N
Oncogene; 2009 Jun; 28(23):2245-56. PubMed ID: 19421142
[TBL] [Abstract][Full Text] [Related]
20. Wnt/β-catenin/LEF-1 signaling in chronic lymphocytic leukemia (CLL): a target for current and potential therapeutic options.
Gandhirajan RK; Poll-Wolbeck SJ; Gehrke I; Kreuzer KA
Curr Cancer Drug Targets; 2010 Nov; 10(7):716-27. PubMed ID: 20578984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
